The aims of this study were: (1) To establish subclones of ALK-translocated NSCLC cell lines with known drug sensitivity and resistance to crizotinib or ceritinib; (2) To identify the EV-associated RNAs involved in transmission of drug resistance and migration capability from ALK-TKI-resistant subclones to drug-sensitive subclones; (3) To determine whether these EV-associated RNAs involved in drug resistance correlate with treatment response in patients with ALK–translocated lung adenocarcinoma. This evidence concerns the gene ALK and non-small cell lung carcinoma.